129 related articles for article (PubMed ID: 26048820)
1. Quantification of caffeine in human saliva by Nuclear Magnetic Resonance as an alternative method for cytochrome CYP1A2 phenotyping.
Schievano E; Finotello C; Navarini L; Mammi S
Talanta; 2015 Aug; 140():36-41. PubMed ID: 26048820
[TBL] [Abstract][Full Text] [Related]
2. Analysis of caffeine and paraxanthine in human saliva with ultra-high-performance liquid chromatography for CYP1A2 phenotyping.
Jordan NY; Mimpen JY; van den Bogaard WJ; Flesch FM; van de Meent MH; Torano JS
J Chromatogr B Analyt Technol Biomed Life Sci; 2015 Jul; 995-996():70-3. PubMed ID: 26038236
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of a reversed-phase HPLC method for CYP1A2 phenotyping by use of a caffeine metabolite ratio in saliva.
Begas E; Kouvaras E; Tsakalof AK; Bounitsi M; Asprodini EK
Biomed Chromatogr; 2015 Nov; 29(11):1657-63. PubMed ID: 25891161
[TBL] [Abstract][Full Text] [Related]
4. Caffeine and paraxanthine HPLC assay for CYP1A2 phenotype assessment using saliva and plasma.
Perera V; Gross AS; McLachlan AJ
Biomed Chromatogr; 2010 Oct; 24(10):1136-44. PubMed ID: 20853468
[TBL] [Abstract][Full Text] [Related]
5. Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers.
Shirley KL; Hon YY; Penzak SR; Lam YW; Spratlin V; Jann MW
Neuropsychopharmacology; 2003 May; 28(5):961-6. PubMed ID: 12644842
[TBL] [Abstract][Full Text] [Related]
6. [Chromatographic determination of caffeine and its metabolites in saliva and plasma].
Filimonova AA; Ziganshina LE; Chichirov AA
Klin Lab Diagn; 2008 Oct; (10):34-6. PubMed ID: 19069442
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of caffeine in plasma and saliva, and the influence of caffeine abstinence on CYP1A2 metrics.
Perera V; Gross AS; Xu H; McLachlan AJ
J Pharm Pharmacol; 2011 Sep; 63(9):1161-8. PubMed ID: 21827488
[TBL] [Abstract][Full Text] [Related]
8. Validation of a high-performance liquid chromatography assay for quantification of caffeine and paraxanthine in human serum in the context of CYP1A2 phenotyping.
Koch JP; ten Tusscher GW; Koppe JG; Guchelaar HJ
Biomed Chromatogr; 1999 Jun; 13(4):309-14. PubMed ID: 10416066
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine.
Carrillo JA; Christensen M; Ramos SI; Alm C; Dahl ML; Benitez J; Bertilsson L
Ther Drug Monit; 2000 Aug; 22(4):409-17. PubMed ID: 10942180
[TBL] [Abstract][Full Text] [Related]
10. Assessment of CYP1A2 activity in clinical practice: why, how, and when?
Faber MS; Jetter A; Fuhr U
Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):125-34. PubMed ID: 16128905
[TBL] [Abstract][Full Text] [Related]
11. Paraxanthine/Caffeine Concentration Ratios in Hair: An Alternative for Plasma-Based Phenotyping of Cytochrome P450 1A2?
De Kesel PM; Lambert WE; Stove CP
Clin Pharmacokinet; 2015 Jul; 54(7):771-81. PubMed ID: 25603821
[TBL] [Abstract][Full Text] [Related]
12. Orientation of caffeine within the active site of human cytochrome P450 1A2 based on NMR longitudinal (T1) relaxation measurements.
Regal KA; Nelson SD
Arch Biochem Biophys; 2000 Dec; 384(1):47-58. PubMed ID: 11147835
[TBL] [Abstract][Full Text] [Related]
13. In vivo evaluation of CYP1A2, CYP2A6, NAT-2 and xanthine oxidase activities in a Greek population sample by the RP-HPLC monitoring of caffeine metabolic ratios.
Begas E; Kouvaras E; Tsakalof A; Papakosta S; Asprodini EK
Biomed Chromatogr; 2007 Feb; 21(2):190-200. PubMed ID: 17221922
[TBL] [Abstract][Full Text] [Related]
14. Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test.
Tantcheva-Poór I; Zaigler M; Rietbrock S; Fuhr U
Pharmacogenetics; 1999 Apr; 9(2):131-44. PubMed ID: 10376760
[TBL] [Abstract][Full Text] [Related]
15. Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva.
Fuhr U; Rost KL
Pharmacogenetics; 1994 Jun; 4(3):109-16. PubMed ID: 7920690
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous Quantification of Antioxidants Paraxanthine and Caffeine in Human Saliva by Electrochemical Sensing for CYP1A2 Phenotyping.
Anastasiadi RM; Berti F; Colomban S; Tavagnacco C; Navarini L; Resmini M
Antioxidants (Basel); 2020 Dec; 10(1):. PubMed ID: 33374269
[TBL] [Abstract][Full Text] [Related]
17. Analysis of urinary caffeine metabolites by HPLC-DAD: the use of metabolic ratios to assess CYP1A2 enzyme activity.
Caubet MS; Elbast W; Dubuc MC; Brazier JL
J Pharm Biomed Anal; 2002 Jan; 27(1-2):261-70. PubMed ID: 11682234
[TBL] [Abstract][Full Text] [Related]
18. [Qualitative and quantitative determination of caffeine in saliva by high performance liquid chromatography].
Napierała M; Florek E
Przegl Lek; 2016; 73(10):777-80. PubMed ID: 29689683
[TBL] [Abstract][Full Text] [Related]
19. Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans.
Bapiro TE; Sayi J; Hasler JA; Jande M; Rimoy G; Masselle A; Masimirembwa CM
Eur J Clin Pharmacol; 2005 Nov; 61(10):755-61. PubMed ID: 16261361
[TBL] [Abstract][Full Text] [Related]
20. The determination of the Paraxanthine/Caffeine ratio as a metabolic biomarker for CYP1A2 activity in various human matrices by UHPLC-ESIMS/MS.
Lajin B; Schweighofer N; Goessler W; Obermayer-Pietsch B
Talanta; 2021 Nov; 234():122658. PubMed ID: 34364467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
